Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN).

Guo, Lixin; Li, Li; Yu, Qiurong; Wang, Na; Chen, Jun; Wang, Zhiquan; Ding, Yuchen

Guo, Lixin; Li, Li; Yu, Qiurong; Wang, Na; Chen, Jun; Wang, Zhiquan; Ding, Yuchen.

Afiliação

Guo L; Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing, China. glx1218@163.com.
Li L; Department of Endocrinology, Ningbo First Hospital, Zhejiang, China.
Yu Q; Department of Endocrinology, Changshu Second People's Hospital, Jiangsu, China.
Wang N; Department of Endocrinology, Qingdao Endocrine and Diabetes Hospital, Shandong, China.
Chen J; Department of Endocrinology, Xiaoshan Affiliate Hospital of Wenzhou Medical University, Hangzhou, China.
Wang Z; Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.
Ding Y; Eli Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, China.

Diabetes Ther ; 13(6): 1231-1244, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35583797

Palavras-chave

Baseline characteristics; Dulaglutide; Post-marketing safety study; T2DM in China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diabetes Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google